Martinus Adrianus van Osch
Fondateur chez Forbion Capital Partners Management Holding BV
Profil
Martinus Adrianus van Osch founded Forbion Capital Partners Management Holding BV in 2007, where he is working as Managing Partner from 2007.
Mr. van Osch also currently works at Mitralign, Inc., as Director, FlowMedica, Inc., as Director, Autonomic Technologies, Inc., as Director, and X-Cell Medical, Inc., as Director.
Mr. van Osch also formerly worked at ACADIA Pharmaceuticals, Inc., as Director, PneumRx LLC, as Director, CircuLite, Inc., as Director, Cambridge Drug Discovery Holdings Ltd., as Director, Pathway Medical Technologies, Inc., as Director, and Roche Innovation Center Copenhagen A, as Director.
Mr. van Osch received his graduate degree from the University of Groningen.
Postes actifs de Martinus Adrianus van Osch
| Sociétés | Poste | Début |
|---|---|---|
X-Cell Medical, Inc.
 X-Cell Medical, Inc. Medical SpecialtiesHealth Technology X-Cell Medical, Inc. develops drugs for cardiovascular clinical applications. It focuses on delivery of drugs with safety and efficacy profiles for cardiovascular indications including restenosis, myocardial infarction and vulnerable plaque. The company was founded in 2002 and is headquartered in Monmouth Junction, NJ. | Directeur/Membre du Conseil | - |
FlowMedica, Inc.
 FlowMedica, Inc. Medical SpecialtiesHealth Technology FlowMedica, Inc. develops intravascular systems and medical devices. The company's products include Benephit CV, PVSolo, PVMini, and XT Infusion systems. It also develops novel, proprietary, and minimally invasive intravascular systems for implementing Targeted Renal Therapy. The company was founded in 2002 and is headquartered in Fremont, CA. | Directeur/Membre du Conseil | - |
Mitralign, Inc.
 Mitralign, Inc. Medical SpecialtiesHealth Technology Mitralign, Inc. operates as a valve repair company that engages in transcatheter annuloplasty system designed to treat both functional tricuspid regurgitation and mitral regurgitation. The Mitralign Percutaneous Annuloplasty System, MPAS, is intended for the treatment of symptomatic functional mitral regurgitation for annular reduction through tissue plication. The company was founded by Paul A. Spence and Richard P. Geoffrion in 2003 and is headquartered in Tewksbury, MA. | Directeur/Membre du Conseil | - |
Forbion Capital Partners Management Holding BV
 Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies. | Fondateur | 08/01/2007 |
Autonomic Technologies, Inc.
 Autonomic Technologies, Inc. Electronic Equipment/InstrumentsElectronic Technology Autonomic Technologies, Inc. develops and commercializes innovative therapies for the treatment of severe headache. Its product, the ATI Neurostimulation System, is used for the treatment of acute pain of cluster headache. The company was founded in 2007 and is headquartered in Redwood City, CA. | Directeur/Membre du Conseil | - |
Anciens postes connus de Martinus Adrianus van Osch
| Sociétés | Poste | Fin |
|---|---|---|
Roche Innovation Center Copenhagen A/S
 Roche Innovation Center Copenhagen A/S Pharmaceuticals: MajorHealth Technology Roche Innovation Center Copenhagen A/S discovers and develops drugs for the treatment of oncology, metabolic diseases, and infectious diseases. The firm manufactures a pipeline of drug candidates that act selectively on disease-related ribonucleic acid to provide patients with novel treatments for both rare and common diseases. It produces pre-clinical and clinical assets for the treatment of a range of diseases including oncology, metabolic diseases, and infectious diseases. The company was founded by Matts Lundwall and Mikael Ørum on January 1, 1998 and is headquartered in Horsholm, Denmark. | Directeur/Membre du Conseil | 02/09/2014 |
| ACADIA PHARMACEUTICALS INC. | Directeur/Membre du Conseil | 09/09/2005 |
Cambridge Drug Discovery Holdings Ltd.
 Cambridge Drug Discovery Holdings Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Charles River Laboratories International, Inc., Cambridge Drug Discovery Holdings Ltd. is a company that researches potential new drugs for the treatment of cancer. The company is based in Cambridge, UK. Cambridge Drug Discovery Holdings was acquired by Charles River Discovery Research Services UK Ltd., part of Charles River Laboratories International, Inc. from November 14, 2005 on June 11, 2001 for $38 million. The British company was founded by Barry Kenny, Jonathan Mark Treherne. | Directeur/Membre du Conseil | - |
PneumRx LLC
 PneumRx LLC Medical SpecialtiesHealth Technology PneumRx, Inc. operates as a medical device company which focuses on developing minimally-invasive solutions for unmet medical needs in pulmonary medicine. Its product is a minimally invasive device intended to improve exercise capacity, lung function, and quality of life in patients with both heterogeneous and homogeneous emphysema. The company was founded by by Erin McGurk, Mark L. Mathis, and Ronald Dieck in 2004 and is headquartered in Mountain View, CA. | Directeur/Membre du Conseil | - |
| ░░░░░░░ ░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | - |
Formation de Martinus Adrianus van Osch
| University of Groningen | Graduate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ACADIA PHARMACEUTICALS INC. | Health Technology |
| Entreprise privées | 10 |
|---|---|
X-Cell Medical, Inc.
X-Cell Medical, Inc. Medical SpecialtiesHealth Technology X-Cell Medical, Inc. develops drugs for cardiovascular clinical applications. It focuses on delivery of drugs with safety and efficacy profiles for cardiovascular indications including restenosis, myocardial infarction and vulnerable plaque. The company was founded in 2002 and is headquartered in Monmouth Junction, NJ. | Health Technology |
FlowMedica, Inc.
FlowMedica, Inc. Medical SpecialtiesHealth Technology FlowMedica, Inc. develops intravascular systems and medical devices. The company's products include Benephit CV, PVSolo, PVMini, and XT Infusion systems. It also develops novel, proprietary, and minimally invasive intravascular systems for implementing Targeted Renal Therapy. The company was founded in 2002 and is headquartered in Fremont, CA. | Health Technology |
Mitralign, Inc.
Mitralign, Inc. Medical SpecialtiesHealth Technology Mitralign, Inc. operates as a valve repair company that engages in transcatheter annuloplasty system designed to treat both functional tricuspid regurgitation and mitral regurgitation. The Mitralign Percutaneous Annuloplasty System, MPAS, is intended for the treatment of symptomatic functional mitral regurgitation for annular reduction through tissue plication. The company was founded by Paul A. Spence and Richard P. Geoffrion in 2003 and is headquartered in Tewksbury, MA. | Health Technology |
Forbion Capital Partners Management Holding BV
Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies. | Finance |
CircuLite, Inc.
 CircuLite, Inc. Medical DistributorsDistribution Services CircuLite, Inc. provided treatment for heart disorders. The company was founded by Paul J. Southworth and Paul Spence in November 2004 and was headquartered in Teaneck, NJ. | Distribution Services |
Roche Innovation Center Copenhagen A/S
Roche Innovation Center Copenhagen A/S Pharmaceuticals: MajorHealth Technology Roche Innovation Center Copenhagen A/S discovers and develops drugs for the treatment of oncology, metabolic diseases, and infectious diseases. The firm manufactures a pipeline of drug candidates that act selectively on disease-related ribonucleic acid to provide patients with novel treatments for both rare and common diseases. It produces pre-clinical and clinical assets for the treatment of a range of diseases including oncology, metabolic diseases, and infectious diseases. The company was founded by Matts Lundwall and Mikael Ørum on January 1, 1998 and is headquartered in Horsholm, Denmark. | Health Technology |
Pathway Medical Technologies, Inc.
 Pathway Medical Technologies, Inc. Medical SpecialtiesHealth Technology Pathway Medical Technologies, Inc. develops, manufactures, and markets medical devices intended for the treatment of arterial disease, specifically the peripheral arterial disease. Pathway Medical Technologies was founded in 1998, and is headquartered in Kirkland, WA. | Health Technology |
PneumRx LLC
PneumRx LLC Medical SpecialtiesHealth Technology PneumRx, Inc. operates as a medical device company which focuses on developing minimally-invasive solutions for unmet medical needs in pulmonary medicine. Its product is a minimally invasive device intended to improve exercise capacity, lung function, and quality of life in patients with both heterogeneous and homogeneous emphysema. The company was founded by by Erin McGurk, Mark L. Mathis, and Ronald Dieck in 2004 and is headquartered in Mountain View, CA. | Health Technology |
Cambridge Drug Discovery Holdings Ltd.
Cambridge Drug Discovery Holdings Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Charles River Laboratories International, Inc., Cambridge Drug Discovery Holdings Ltd. is a company that researches potential new drugs for the treatment of cancer. The company is based in Cambridge, UK. Cambridge Drug Discovery Holdings was acquired by Charles River Discovery Research Services UK Ltd., part of Charles River Laboratories International, Inc. from November 14, 2005 on June 11, 2001 for $38 million. The British company was founded by Barry Kenny, Jonathan Mark Treherne. | Commercial Services |
Autonomic Technologies, Inc.
Autonomic Technologies, Inc. Electronic Equipment/InstrumentsElectronic Technology Autonomic Technologies, Inc. develops and commercializes innovative therapies for the treatment of severe headache. Its product, the ATI Neurostimulation System, is used for the treatment of acute pain of cluster headache. The company was founded in 2007 and is headquartered in Redwood City, CA. | Electronic Technology |
